Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and Duchenne Muscular Dystrophy. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with delivery of genetic […]
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s. These disorders impact memory, movement, language, behavior, and personality resulting in disability and death of millions of patients. […]
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by several orders of magnitude. No technology currently exists that can sequence the amino acids of proteins at a single molecule level. To change this, Glyphic is developing a next generation […]